DexCom Director Sells $178,080 in Stock (DXCM)
DexCom (NASDAQ:DXCM) Director Barbara Kahn sold 4,000 shares of the company’s stock on the open market in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $44.52, for a total transaction of $178,080.00. Following the completion of the sale, the director now directly owns 49,525 shares of the company’s stock, valued at approximately $2,204,853. The sale was disclosed in a filing with the SEC, which is available at this link.
Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of DexCom in a research note on Friday, August 8th. They now have a $46.00 price target on the stock. Separately, analysts at Raymond James reiterated an “outperform” rating on shares of DexCom in a research note on Thursday, August 7th. They now have a $46.00 price target on the stock, up previously from $44.00. Finally, analysts at Canaccord Genuity raised their price target on shares of DexCom from $40.00 to $48.00 in a research note on Thursday, August 7th. They now have a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and seven have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $41.00.
Shares of DexCom (NASDAQ:DXCM) traded up 1.40% on Tuesday, hitting $44.82. 519,781 shares of the company’s stock traded hands. DexCom has a 52-week low of $25.49 and a 52-week high of $49.83. The stock has a 50-day moving average of $41.18 and a 200-day moving average of $39.11. The company’s market cap is $3.383 billion.
DexCom (NASDAQ:DXCM) last announced its earnings results on Wednesday, August 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. The company had revenue of $58.80 million for the quarter, compared to the consensus estimate of $52.45 million. During the same quarter in the previous year, the company posted ($0.14) earnings per share. The company’s revenue for the quarter was up 64.2% on a year-over-year basis. Analysts expect that DexCom will post $-0.32 EPS for the current fiscal year.
DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.